...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Quality of life (QoL): impact of specific immunotherapy (SIT) on social and physical ability.
【24h】

Quality of life (QoL): impact of specific immunotherapy (SIT) on social and physical ability.

机译：生活质量（QoL）：特异性免疫疗法（SIT）对社交和身体能力的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The World Allergy Organization (WAO) task force recommendations for standardization of clinical trials with allergen-specific im-munotherapy for respiratory allergy state that, with respect to quality of life (QoL), focusing on clinical manifestations alone might not reflect the burden of allergic diseases. This stems from evidence indicating that allergy is a systemic disease resulting in non-organ-specific symptoms such as tiredness or lack of concentration (1). Despite this, symptom score and medication score, which do not fully reflect patients' perceptions of how treatment affects the disease burden, are often utilized as the only end-points in clinical trials. While QoL questionnaires for both rhinitis and asthma have been developed and validated in many languages, only a small number of trials examining the effects of specific allergen im-munotherapy have considered QoL in assessing the efficacy of treatment.
机译：世界过敏组织（WAO）工作组针对呼吸道过敏的过敏原特异性免疫疗法的临床试验标准化的建议，关于生活质量（QoL），仅关注临床表现可能无法反映出过敏的负担疾病。这源于证据表明过敏是一种全身性疾病，会导致非器官特异性症状，如疲倦或精神不集中（1）。尽管如此，症状评分和药物评分并不能完全反映患者对治疗如何影响疾病负担的看法，通常被用作临床试验的唯一终点。虽然针对鼻炎和哮喘的QoL问卷已经用多种语言开发和验证，但只有少数检查特定变应原免疫疗法效果的试验在评估治疗效果时考虑了QoL。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号